Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Wellcome Centre for Human Genetics researcher Dr Ross Chapman has been selected has one European Molecular Biology Laboratory's Young Investigators for 2018.

The EMBO Young Investigator Programme identifies recent group leaders with a proven record of scientific excellence and offers them access to a range of benefits during their four-year tenure. These include an award of 15,000 euros, with the potential for additional funding, mentorship by a senior scientist from the community of EMBO Members, access to training in leadership skills and responsible research practices, as well as networking opportunities.

Read the full article

Similar stories

Côte d’Ivoire becomes first nation to deploy R21 malaria vaccine

Côte d’Ivoire will become the first country to roll-out the new R21/Matrix-M™ vaccine with the first child vaccinated in Abidjan, marking a critical step and historic milestone in the global fight against malaria. 15 African countries are expected to introduce malaria vaccines with Gavi support in 2024, and countries plan to reach around 6.6 million children with the malaria vaccine in 2024 and 2025. The new vaccine has been authorised by Ghana, Nigeria, Burkina Faso and the Central African Republic, and many others are preparing to receive shipments.